Objectives: To investigate the effect of macrophage conditioned media on fibroblast activation. Methods: PBMC-derived macrophages from healthy control (n=3 females, mean age 50.8±21.9 years) and diffuse scleroderma (n=4 females, mean age 54.8±15.7 years, mean disease duration 73.2±90.3 months, 2 with antiScl70 and 2 with antiRNA polymerase antibodies) individuals were cultured in RPMI/10% FBS/M-CSF (4ng/ml)/P/S, quiesced in media with 1% BSA replacing the FBS, and left untreated (M0) or treated with IL-6 (50ng/ml, M (IL-6)) for 24 hours. The cultures were replaced with fresh media and collected after 24 hours. Conditioned media were applied to healthy control skin fibroblasts (24 hours) and fibroblast expression of fibrotic proteins was assessed by Western Blot, using β-tublin and TBP as loading controls. As control, fibroblasts from healthy volunteers were left untreated by culturing in non-conditioned media (fresh RPMI/ 1% BSA/M-CSF (4ng/ml)/P/S).
Background: Systemic sclerosis (SSc) is a chronic connective tissue disorder characterized by microvascular injury, fibrosis and autoimmunity that affects the skin and internal organs. The short-term activation of peripheral blood T lymphocytes plays a crucial role in initiating and maintaining the chronic inflammation. The transient increase of the cytoplasmic free calcium level plays a key role in the process of lymphocyte activation. Kv1.3 and IKCa1 potassium channels are important regulators of the maintenance of calcium influx during lymphocyte activation. The influx of calcium is maintained by the function of potassium channels that conserve the electrochemical potential gradient via the efflux of potassium from the cytoplasm. Recent reports raised the notion that the inhibition of lymphocyte potassium channels, especially that of the Kv1.3 channel would be an straightforward solution for specific immunosuppression in autoimmune disorders. Furthermore, our previous studies described an alteration of the short-term activation of peripheral lymphocytes in rheumatoid arthritis and primary Sjögren's syndrome (pSS), and the overexpression of Kv1.3 channels in pSS. Objectives: Therefore, in this study we aimed to characterize the effects of lymphocyte potassium channel inhibition on short-term peripheral blood T lymphocyte activation in major lymphocyte subsets in SSc. Methods: We enrolled 12 healthy individuals and 16 SSc patients. We evaluated calcium influx kinetics following activation in CD4, Th1, Th2 and CD8 cells applying a novel kinetic flow cytometry approach. We assessed the sensitivity of the above subsets to specific inhibition of the Kv1.3 and IKCa1 potassium channels. We also assessed the Kv1.3 expression on lymphocytes. Results: We observed increased parameters of calcium influx in CD8+ lymphocytes' as compared with Th1 cells in SSc. However, the activation of CD8+ cells was lower in SSc compared to healthy controls. Moreover, activation of Th1 lymphocytes was slower in SSc than in healthy controls. The inhibition of IKCa1 potassium channel decreased the activation of CD8+ lymphocytes in healthy controls and the activation of Th1 cells in SSc. Background: Scleroderma (SSc) is a disease that shows involvement in internal organs or on the skin characterized by fibrosis (1). Dermis thickening and uncontrolled extracellular matrix (ECM) increase are seen in this disease whose pathogenesis is not fully understood. TGF-β/Smad 2&3 pathway is pivotal role in SSc pathogenesis via induction of profibrotic molecules including collagen and by decrease of matrix metalloproteinases (MMPs) synthesis (2,3). The occurrence of the myofibroblast phenotype at fibrosis is thought to be responsible for the contracted regions of the affected tissues (4). Objectives: The aim of this study with bleomycin (BLM) formed in an experimental model of scleroderma is to investigate the potential effects of epigallocatechin-3-gallate (EGCG) against fibrosis. Methods: 32 Balb/c female mice were randomly selected into four groups.For 21 days: (1) Control group (n: 8) was given 100 μ L subcutan (sc) saline (SF) once a day, 100 μL intraperitoneal (ip) SF twice a week, (2) BLM group (n: 8) was given 100 μL (100 ug) sc BLM once a day, 100 μL ip SF twice a week, (3) BLM + EGCG group (n:8) was given 100 μL (100 ug) sc BLM once a day, 100 μL (100 μg) ip EGCG twice a week, (4) EGCG group (n: 8) was given 100 μL sc SF once a day, 100 mL (100 μg) ip ECCG twice a week. Hematoxylin&eosin and Masson trichrome staining of dermal areas were performed. Myofibroblast activity was measured using alpha smooth muscle actin antibody (αSMA) by immunohistochemistry.Expression levels of MMP-1, MMP-8, MMP-13 and p-SMAD protein were examined by western blot. Expression levels of TGF-β mRNA were examined by qPCR. All of the statistical analyses were performed using SPSS software and the quantitative data were expressed as the means±SEM.The quantitative variables were compared using the a ANOVA-Sidak. Statistical significance was defined as p<0. Background: Systemic sclerosis (SSc) is a chronic fibrosing autoimmune disease which leads to severe musculoskeletal dysfunction, disability and contractures. Little is known on the type and extent of physical therapy (PT) prescribed to SSc patients in daily practice. Objectives: To determine the type and frequency of PT received by SSc patients. Methods: The data of 3430 clinically well defined SSc patients registered in the database of the German Network for Systemic Sclerosis were analyzed using SPSS. Results: 48,5% (1662/3430) of the patients were treated with PT. The most frequently used form of PT was lymphatic drainage (23,6%/876), followed by physical exercise therapy (22%/817) and paraffin wax bath (10,5%/389). About half of the patients (46,9%) received two or three different forms of PT simultaneously. The prescription of PT did not correlate with the SSc subtype, as 49,5% (503/1016) of dcSSc patients, 50,3% (850/1689) of lcSSc patients and 45,7% (143/313) of SSc-Overlap patients received PT. PT was significantly more often prescribed to patients with pulmonary fibrosis in 51,1% (617/1208), synovitis in 61,6% (299/485) and CK elevation in 61,1% (174/285) (p=0,001-0,029). PT did not correlate with the extent of skin fibrosis as measured by mRSS. Interestingly, patients with joint contractures (45,5%) (388/853) or tendon friction rubs (40,6%) (114/281) received significantly less often PT (p=0,006/ 0,045). Comparing the prescription of PT during the initial period 2003-2008 (49,1%; 1937/3942) with the follow up period 2009-2013 (45,3%; 2217/4899) , a significant decrease of PT prescription was observed (p<0,001). Patterns of PT prescription differed significantly between medical subspecialties (p<0,005) i.e. rheumatologists, dermatologists. Conclusions: Although SSc is characterized by considerable disability and restriction of motion, less than 50% of patients received PT. The significant decrease in PT prescription during recent years may reflect lack of knowledge how to prescribe PT and more restrictive insurance regulations. Background: Systemic sclerosis (SSc) is a rare, debilitating connective tissue disease characterized by immunological alterations, vasculopathy and progressive skin and multiorgan fibrosis. The autoimmune dysregulation in SSc comprises lymphocyte activation that leads to autoantibody production, abnormal production of cytokines and chemokines, and impairment of the innate immunity. Recent research has shown that the T cell activation and especially T helper cells play an important role in the pathogenesis of SSc. Amongst them are the proinflammatory Th17 cells. Objectives: To investigate T-cell activation, the percentage of Th17 cells and the circulating cytokine profile in SSc. Methods: We enrolled a total of 24 SSc patients and 16 healthy controls in the study and divided the patients as having diffuse cutaneous SSc (dcSSc, n=13) or limited cutaneous SSc (lcSSc, n=11). Peripheral venous blood samples were collected from all subjects. We examined the percentage of activated T cells (unstimulated and upon stimulation with PHA-M) and of Th17 cells by flow cytometry in both patients and controls. We used ELISA to quantitate the serum levels of human IL-6, TGF-β1, and IL-17A. Results: We identified a decreased percentage of activated T cells (CD3+CD69+) in PHA-stimulated samples from SSc patients in comparison with healthy controls, p<0.001. However, we did not establish a correlation between the down-regulated CD3+CD69+ cells and the SSc phenotype. With regard to Th17 cells, our patients demonstrated increased percentage as opposed to controls, p=0.031. We detected up-regulated Th17 cells within the lcSSc subset against controls, p=0.025. However, no difference was found between dcSSc and lcSSc patients. Regarding the peripheral cytokine profile, we detected raised levels of IL-6, p<0.001, TGF-β1, p=0.02, and IL-17A, p<0.001 in patients when compared to controls. Furthermore, we found increased circulating TGF-β, IL-6 and IL-17A in the lcSSc subset versus healthy individuals, as it follows TGF-β1, p=0.031, IL-6, p<0.001, and IL-17A, p<0.001. Furthermore, circulating IL-17A was higher in lcSSc as opposed to dcSSc subset, p=0.008. Within the dcSSc phenotype, we detected raised levels of IL-17A and IL-6 versus controls: IL-17A, p<0.001, IL-6, p<0.001. Conclusions: Our results demonstrate down-regulated T-cell activation upon PHA-stimulation along with pronounced peripheral Th17 profile, and related cytokines in SSc patients, suggesting their implication in the pathogenesis of SSc. 
